Telavancin: A novel lipoglycopeptide antibiotic
Authors:
Open Access
- 1 June 2011
- journal article
- molecules of-the-millennium
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 2 (2) , 135-137
Abstract
J Pharmacol Pharmacother, Official publication of InPharm Association, IndiaKeywords
This publication has 12 references indexed in Scilit:
- Management of Infections Caused by Vancomycin-Resistant Gram-Positive BacteriaThe Pediatric Infectious Disease Journal, 2010
- Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum ofStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2010
- 2009 FDA drug approvalsNature Reviews Drug Discovery, 2010
- Methicillin and vancomycin resistant S. aureus in hospitalized patientsJournal of Global Infectious Diseases, 2010
- Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid IIAntimicrobial Agents and Chemotherapy, 2009
- Vancomycin-ResistantStaphylococcus aureus,Michigan, USA, 2007Emerging Infectious Diseases, 2009
- Postantibiotic Effects of Telavancin against 16 Gram-Positive OrganismsAntimicrobial Agents and Chemotherapy, 2009
- Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 2008
- Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive OrganismsClinical Infectious Diseases, 2008
- The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008